A Randomized, Double-blind, Placebo-controlled, Doseescalation Trial to Evaluate the Safety and Tolerability of a Single IV Administration of Dasiglucagon and the Bioavailability of Dasiglucagon Following SC Compared to IV Administration in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 27 Jun 2019
Price : $35 *
At a glance
- Drugs Dasiglucagon (Primary) ; Dasiglucagon (Primary)
- Indications Hypoglycaemia
- Focus Adverse reactions
- Sponsors Zealand Pharma
- 25 Jun 2019 Status changed from recruiting to completed.
- 05 Apr 2019 Planned End Date changed from 20 Feb 2019 to 28 Jun 2019.
- 05 Apr 2019 Planned primary completion date changed from 20 Jan 2019 to 28 Jun 2019.